STOK
NASDAQ · Biotechnology
Stoke Therapeutics Inc
$26.60
+0.53 (+2.03%)
Financial Highlights (FY 2026)
Revenue
202.39M
Net Income
-7,558,135
Gross Margin
—
Profit Margin
-3.7%
Rev Growth
+145.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 60.0% | 60.0% | 60.0% |
| Operating Margin | -11.2% | -16.2% | -13.4% | -15.6% |
| Profit Margin | -3.7% | -11.6% | -13.8% | -12.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 202.39M | 323.22M | 315.22M | 266.09M |
| Gross Profit | — | 193.80M | 189.00M | 159.55M |
| Operating Income | -22,586,328 | -52,228,751 | -42,169,219 | -41,424,051 |
| Net Income | -7,558,135 | -37,471,003 | -43,595,472 | -34,080,935 |
| Gross Margin | — | 60.0% | 60.0% | 60.0% |
| Operating Margin | -11.2% | -16.2% | -13.4% | -15.6% |
| Profit Margin | -3.7% | -11.6% | -13.8% | -12.8% |
| Rev Growth | +145.9% | +14.4% | -1.8% | +5.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 797.73M | 940.05M | 930.40M |
| Total Equity | — | 1.37B | 1.45B | 1.33B |
| D/E Ratio | — | 0.58 | 0.65 | 0.70 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -20,653,271 | -52,091,948 | -53,358,586 | -46,407,378 |
| Free Cash Flow | — | -52,998,459 | -42,607,892 | -40,994,477 |